Press

MAR | Acarix accelerates US market entry with Proximo Medical as commercialization partner   PR Acarix Accelerates US Market eng PR Acarix Accelerates US Market swe            

MAR | Acarix US expansion to be a major contributor to the company’s new financial and operational goals   PR Acarix Guidance eng          

Acarix Notice to EGM   Acarix Notice to EGM (eng) Acarix Notice to EGM (swe)          

MAR | Acarix Rights Issue Launch Release   Rights Issue Launch Release (eng) Rights Issue Launch Release (swe)              

Acarix granted US CPT reimbursement code for CADScor System   Acarix PR CADScor ENG            

New health economic study proves the value of CADScor® in coronary disease diagnostics   Acarix PR CADScor HEOR publication SWE Acarix PR CADScor HEOR publication ENG            

Initial Dan-NICAD II results presented today at ESC   PR Acarix Dan-NICAD II abstract session SWE >> PR Acarix Dan-NICAD II abstract session ENG >>            

Preliminary Dan-NICAD II results to be presented at ESC   PM Acarix Dan-NICAD II SWE PM Acarix Dan-NICAD II ENG            

Acarix AB (publ) publishes Interim Report, January – June 2021     PR Acarix Q2 2021 eng >> PM Acarix Q2 2021 sv >> Acarix Q2 2021 eng >> Acarix Q2 2021 sv >>            

Acarix Publishes the Annual Report for 2020   Today, Tuesday April 20, Acarix is publishing its Annual Report for 2020 on the company website www.acarix.com. The Annual Report is also attached to this press release.   PM_Acarix_Year-End_2020 eng Acarix_ÅR_...

FDA identifies exclusive code for the CADScor®System   After yesterday’s announcement and further analysis of the FDA approval,Acarix AB today announce that the company’s marketing approval of the CADScor®System in the US was granted under a new generic ty...

Acarix changes Certified Advisor to Redeye   Acarix AB (publ) announces today that the company has entered into anagreement with Redeye AB regarding the position as Certified Adviser.Redeye AB will take over as Certified Adviser on October 19, 2020. Acarix...

Acarix carries out a directed issue of shares to guarantors in conjunction with the oversubscribed rights issue   Acarix AB (”Acarix” or the "Company") has, as previously announced, completed the rights issue ofshares amounting to approximately SEK 56 mill...

Last day of trading in paid subscribed shares (Sw. BTA)   Last day of trading in subscribed paid shares ("BTA") in Acarix AB ("Acarix" or the “Company") willbe Thursday the 1 October 2020 and stop day will be Monday the 5 October 2020.In the rights issue, ...

Acarix announce final outcome in oversubscribed rights issue   Acarix AB ("Acarix" or the "Company") has completed the new share issue of a maximum of86,156,738 shares with preferential rights for the Company's existing shareholders, which wasresolved by t...

The board of directors of Acarix AB ("Acarix" or the "Company") has, subject to the subsequent approval of an Extraordinary General Meeting, resolved to carry out a new share issue of a maximum of 86,156,738 shares with preferential rights for the Company'...

Acarix publishes a supplement to the prospectus The board of directors of Acarix AB ("Acarix" or the "Company") has prepared a supplement to theprospectus regarding invitation to acquire shares in the approved preferential rights issue in Acarixwhich was a...

Acarix VD Per Persson presenterade på Redeye   Vid en investerarpresentation på Redeye den 25 augusti utvecklade Acarixsvd Per Persson hur han ser på bolaget och den pågåendeföreträdesemissionen. Han gav också en uppdatering kring bolagetsframsteg. Acarix_...

Acarix publishes prospectus in connectionwith rights issue of approximately SEK 56 million     Acarix_PR_publication_of_prospectus (1) Acarix_PM_offentliggörande_prospekt

Acarix AB (publ) publishes Interim Report, January – June 2020 For us and for many other companies, the pandemic and global uncertainty have caused delays in someprioritized projects. However, in combination with a dynamic capital market this has created a...

The board of directors of Acarix AB ("Acarix" or the "Company") has, subject to the subsequent approval of an Extraordinary General Meeting, resolved to carry out a new share issue of a maximum of 86,156,738 shares with preferential rights for the Company'...

Press release MAR | Successful rights issue enables increasedfocus on strategic initiatives   The fourth quarter of 2019 was eventful, and we had the opportunity to see progressin several areas. Importantly, we closed a rights issue of SEK 43 million, befo...

Acarix AB (publ) today announced the initiation of the randomized, multicenter clinical study FILTER-SCAD to examine the cost effectiveness and safety of adding the CADScor®System as a rule-out test in patients referred with symptoms suggestive of stable c...

Acarix finalized a rights issue to finance further market expansion

Press release MAR |Acarix announce final outcome in rights issue   Acarix AB ("Acarix" or the "Company") has completed the new share issue of a maximum of34,541,064 shares with preferential rights for the Company's existing shareholders, which wasresolved ...

The board of directors of Acarix AB ("Acarix" or the "Company") has today, pursuant to the authorization granted by the extra general meeting on 16 August 2019, resolved to carry out a new share issue of a maximum of 34,541,064 shares with preferential rig...

MAR | Announcement from Acarix's extra general meeting The extra general meeting ("EGM") of Acarix AB ("Acarix" or the "Company") was held today on 16 August 2019 and the following resolutions were passed by the meeting. Announcement from Acarix's extra ge...

MAR | Interim Report January – June 2019   ”With CADScor®System we have a fantastic opportunity to revolutionize the way the healthcare system handles patients with suspected coronary artery disease, CAD. In our daily work at Acarix, we see that the need f...

MAR | Announcement from Acarix’s annual general meeting May 2019   May 16, 2019 The annual general meeting (“AGM”) of Acarix AB (“Acarix” or the “Company”) was held today on 16 May 2019 and the following resolutions were passed by the meeting. Adoption of ...

MAR | Interim report, January – March 2019 May 16, 2019   ”After almost a year at Acarix, I am truly inspired by the opportunities our products offer to revolutionize heart diagnosis. We participate actively in congresses and scientific conferences and...

MAR | Acarix publishes annual report for 2018   April 25, 2019 Today, Thursday April 25, Acarix is publishing its Annual Report for 2018 on the company website www.acarix.com. The Annual Report is found here. For further information, please contact:Per Per...

Press release MAR | Market dynamics favourable for CADScor®System, addressing the challenges of the global healthcare market   ”After six months at Acarix, I clearly see our market evolving and a growing opportunity for our products aimed at revolutioniz...

MAR | Submission of new dossier by the end of February 2019   Jan 15, 2019 Acarix AB (publ) (ACARIX: FN Stockholm) today announced it will file for German reimbursementdirectly with the Federal Joint Committee (G-BA) for its CADScorSystem®. Previously, Aca...

MAR | Interim Report, January – September 2018   Nov 14, 2018 ”During the quarter we proudly reported that Kristianstad Central Hospital in Sweden evaluated the CADScor®System with a positive outcome. Due to the good result the hospital´s clinical manageme...

MAR | Acarix (FN STO: ACARIX) today announced that the board of directors has appointed Per Persson to Chief Executive Officer Nov 13, 2018 Per Persson comes directly from the role as Chief Commercial Officer of Acarix. Christian Lindholm, who has served ...

MAR | Interim Report, January – June 2018   Acarix gains traction in key markets providing physicians and patients new opportunities ”Since the inception of Acarix, the company has been fully committed to developing a reliable, noninvasive and radiation-fr...

MAR | Interim, Januari – March 2018   CADScor®System launched in key markets   “Acarix introduced the CADScor®System on the German, Swedish and Danish markets 11 months ago, in June 2017. The introduction was made without general reimbursement, which is on...

MAR | Annual report 2017   Today, Monday April 23, Acarix is publishing its Annual Report for 2017. For further information please contact:Christian Lindholm, Interim CEOE-mail: secli@acarix.comPhone: +46 705 118333 This information is information that Aca...

MAR | Year-end Report January-December 2017   CADScor®System launched in key markets ”In 2017, we achieved historic milestones in Acarix – most noticeably the receipt of our first commercial order for CADScor®System in June and thus a confirmation of the c...